Phase 2 Study of ET-743 in Persistent or Recurrent Endometrial Carcinoma - Tabular View

Tracking Information
First Received Date ^ICMJE	December 9, 2002
Last Updated Date	June 23, 2005
Start Date ^ICMJE
Primary Completion Date
Current Primary Outcome Measures ^ICMJE
Original Primary Outcome Measures ^ICMJE
Change History	Complete list of historical versions of study NCT00050440 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^ICMJE
Original Secondary Outcome Measures ^ICMJE

Descriptive Information
Brief Title ^ICMJE	Phase 2 Study of ET-743 in Persistent or Recurrent Endometrial Carcinoma
Official Title ^ICMJE
Brief Summary	This is a study is to test the safety and effectiveness of an investigational chemotherapy agent in subjects with persistent or recurrent endometrial cancer. After a subject meets all entry criteria and signs informed consent she will be enrolled in the study. Participants will be required to attend regular clinic visits to receive study medication and have their status monitored. They will also be required to have radiologic tumor assessments performed at multiple times throughout the study. A detailed explanation can be provided by the investigator conducting this study.
Detailed Description
Study Phase	Phase II
Study Type ^ICMJE	Interventional
Study Design ^ICMJE	Treatment
Condition ^ICMJE	Endometrial Neoplasms
Intervention ^ICMJE	Drug: ET-743
Study Arms / Comparison Groups
Publications *
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Completed
Enrollment ^ICMJE
Completion Date
Primary Completion Date
Eligibility Criteria ^ICMJE	Female subjects 18 years of age or older Diagnosis of advanced or metastatic endometrial carcinoma Progressive disease after 1 cytotoxic chemotherapy regimen given for advanced/metastatic disease At least one measureable tumor lesion Adequate bone marrow, hepatic and renal function Performance status ECOG 0 or 1
Gender	Female
Ages	18 Years and older
Accepts Healthy Volunteers	No
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE	United States

Administrative Information
NCT ID ^ICMJE	NCT00050440
Responsible Party
Study ID Numbers ^ICMJE	ET743-USA-1
Study Sponsor ^ICMJE	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Collaborators ^ICMJE	PharmaMar
Investigators ^ICMJE
Information Provided By	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Verification Date	April 2005
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP